Thursday, January 19, 2012
Following a long run of funding a substantial portion of its
research through institute-wide deals with pharmas, The Scripps Research Institute is now
shifting to more focused collaborations with midsize biotechs. Scripps believes
biotechs are a better fit for the institute's platform technologies than
pharmas, where platforms can get lost in the companies' disease-oriented franchise
Osherovich, L. SciBX 5(3); doi:10.1038/scibx.2012.61 Published online Jan.
1. Cain, C. SciBX 4(5);
AND INSTITUTIONS MENTIONED
Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind.
GlaxoSmithKline plc (LSE:GSK; NYSE;GSK), London, U.K.
Human Genome Sciences Inc. (NASDAQ:HGSI), Rockville, Md.
Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J.
Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland
Pfizer Inc. (NYSE:PFE), New York, N.Y.
Sanford-Burnham Medical Research Institute, La Jolla, Calif.
Scripps Florida, Jupiter, Fla.
The Scripps Research Institute, La Jolla, Calif.
Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan
University of California, Berkeley, Calif.